The USFDA has approved sutimlimab to decrease the need for blood transfusion due to hemolysis in adults with cold agglutinin disease. It is the first and only drug approved for cold agglutinin disease that inhibits the destruction of red blood cells. Sutimlimab It is a monoclonal antibody that selectively targets the classical complement pathway. It inhibits the complement cascade of the immune system.
It inhibits activated hemolysis and prevents the destruction of healthy blood cells. Do you think sutimlimab will be useful to prevent the need for blood transfusion in patients with hemolysis? Source: FDA, Drugs.com
